SCHEMBL7080254

SCHEMBL7080254

CCCC(=O)NS(=O)(=O)c1ccccc1NC(=O)c1cccc(Oc2ccccn2)c1

nearest known ligand 0.47

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
SMN1; SMN2 Q16637 1/20 0.44
LOX P28300 4/20 0.43
LOXL2 Q9Y4K0 4/20 0.43
ALDH1A1 P00352 3/20 0.42
RAB9A P51151 2/20 0.42
NPC1 O15118 1/20 0.42
TP53 P04637 1/20 0.42
PKM P14618 1/20 0.42
MTNR1B P49286 1/20 0.40
ADORA3 P0DMS8 1/20 0.40
KAT6A Q92794 1/20 0.40
TSHR P16473 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7080300 0.88 ALDH1A1 (0.48) MEN1KMT2ASMN1; SMN2ALDH1A1RAB9A
SCHEMBL7080328 0.86 MEN1 (0.48) MEN1KMT2ASMN1; SMN2RAB9ANPC1
SCHEMBL7076725 0.83 MTNR1B (0.48) MEN1KMT2ASMN1; SMN2ALDH1A1RAB9A
SCHEMBL7078520 0.82 ALDH1A1 (0.53) MEN1KMT2ASMN1; SMN2ALDH1A1TSHR
SCHEMBL7080642 0.82 ALDH1A1 (0.42) MEN1KMT2ASMN1; SMN2ALDH1A1RAB9A
SCHEMBL7083365 0.82 RAB9A (0.42) MEN1KMT2ASMN1; SMN2ALDH1A1RAB9A
SCHEMBL7083338 0.79 MEN1 (0.44) MEN1KMT2ASMN1; SMN2ALDH1A1RAB9A
SCHEMBL7077439 0.79 ALDH1A1 (0.44) MEN1KMT2ASMN1; SMN2ALDH1A1RAB9A
SCHEMBL7081565 0.79 USP2 (0.47) MEN1KMT2ASMN1; SMN2ALDH1A1RAB9A
SCHEMBL7077442 0.79 SMPD1 (0.55) MEN1KMT2ATP53KAT6A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030162818-A1 Acylsulfonamide derivative AJINOMOTO CO. INC. (JP) 2003-08-28 US disclosed
US-6555584-B1 Acetyl-coa carboxylase inhibitors AJINOMOTO CO., INC. (JP) 2003-04-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030162818-A1 Acylsulfonamide derivative ACSS2, ACACA, FASN MEN1 4502/4885KMT2A 934/4885SMN1; SMN2 1718/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.